Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy

Arthritis Care and Research

Volumn 13, Issue 4, 2000, Pages 213-226

  Griffiths, Robert I ^a,b,f   Bar Din, Miriam ^c   MacLean, Catherine H ^d   Sullivan, Erin M ^c   Herbert, Robert J ^c   Yelin, Edward H ^e  

^a Project HOPE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UK   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Project HOPE Center for Health Affairs   (United States)

Author keywords

Costs; Drug therapy; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CORTICOSTEROID; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE ORGANIZATION; PRESCRIPTION; RHEUMATOID ARTHRITIS;

EID: 0033813624     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/1529-0131(200008)13:4<213::aid-anr6>3.0.co;2-2     Document Type: Article

References (43)

1. Rheumatoid arthritis: Pathophysiology and implications for therapy
2. The epidemiology of rheumatoid arthritis: An update
3. Morbidity impact of rheumatoid arthritis on society
4. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States
5. Epidemiology of rheumatoid arthritis
6. Guidelines for the management of rheumatoid arthritis
7. Rheumatoid arthritis and mortality: A longitudinal study in Pima Indians
8. The mortality of rheumatoid arthritis
9. Mortality in rheumatoid arthritis
10. The costs of rheumatoid arthritis: A patient-oriented study of chronic disease costs
11. The lifetime economic costs of rheumatoid arthritis
12. A comparison of the treatment of rheumatoid arthritis in health maintenance organizations and fee-for-service practices
13. A multicenter study of annual health service utilization and costs in rheumatoid arthritis
14. Risk factors for hospitalization and surgery in patients with rheumatoid arthritis: Implications for capitated medical payment
15. A multicenter study of hospitalization in rheumatoid arthritis: Frequency, medical-surgical admissions, and charges
16. Health outcomes for a chronic disease in prepaid group practice and fee for service settings: The case of rheumatoid arthritis
17. The total cost of care and the use of pharmaceuticals in the management of rheumatoid arthritis: The Medi-Cal program
18. The costs of rheumatoid arthritis
19. The economic impact of arthritis
20. The total costs of drug therapy for rheumatoid arthritis: A model based on costs of drug, monitoring, and toxicity
21. The underestimated long term medical and economic consequences of rheumatoid arthritis
22. Health care utilization and outcomes among persons with rheumatoid arthritis in fee-for-service and prepaid group practice settings
23. The costs of rheumatoid arthritis: Absolute, incremental, and marginal estimates
24. Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: The importance of drug and surgery costs
25. A summary of economic evaluations published in the field of rheumatology and related disciplines
26. Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls
27. The burden of rheumatoid arthritis: Facts and figures
28. The impact of rheumatoid arthritis and osteoarthritis: The activities of patients with rheumatoid arthritis and osteoarthritis compared to controls
29. The work dynamics of the person with rheumatoid arthritis
30. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
31. Clinical experience with leflunomide in rheumatoid arthritis
32. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis
33. Treatment of patients With refractory rheumatoid arthritis with extracorporeal protein A immunoadsorption columns: A pilot trial
34. The Prosorba column for treatment of refractory rheumatoid arthritis: A randomized, double-blind, sham-controlled trial
35. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials
36. The sensitivity and specificity of computerized databases for the diagnosis of rheumatoid arthritis
37. Sensitivity and positive predictive value of Medicare part B physician claims for rheumatologic diagnoses and procedures
38. A comparison of the cost-effectiveness of Sertraline versus tricyclic antidepressants in primary care
39. An assessment of the annual and long-term direct costs of rheumatoid arthritis: The impact of poor function and functional decline